Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CNXU

Conexeu Sciences Inc

7.93

Aug 04 • 10:00 AM ET +0.16 (2.13%)

Healthcare Biotechnology USA Micro NASD

Peers: CGEM RIGL ARVN GERN BBOT XNCR CTMX JANX KURA IDYA

Scroll to Statements

Index	-
Market Cap	212.06M
Enterprise Value	204.76M
Income	-
Sales	-
Book/sh	0.27
Cash/sh	0.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	May 21, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	29.47
P/C	29.05
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.89
Current Ratio	7.89
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.10
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-950.49% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-519.42%
Sales Q/Q	-
Earnings	Jul 01
EPS/Sales Surpr.	0.00% -

Insider Own	57.94%
Insider Trans	1.32%
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.62%
SMA50	-29.13%
SMA200	-29.36%
Trades

Shs Outstand	26.76M
Shs Float	11.26M
Short Float	1.52%
Short Ratio	1.62
Short Interest	0.17M
52W High	18.79 -57.83%
52W Low	7.10 11.62%
Volatility	12.84% 14.93%
ATR (14)	1.28
RSI (14)	40.54
Beta	-
Rel Volume	0.89
Avg Volume	105.64K
Volume	11,611

Perf Week	1.73%
Perf Month	-26.62%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-41.30%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	20.00
Prev Close	7.76
Price	7.93
Change	2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-26	Initiated	H.C. Wainwright	Buy	$20

Aug-03-26 10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (Ipo Edge) -6.62%
Jul-15-26 11:01AM	The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. (PR Newswire) +17.68%
Jul-14-26 08:30AM	The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It (GlobeNewswire) -8.12%
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-07-26 09:45AM	A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire) -12.13%
09:00AM	Loading…
09:00AM	A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill (GlobeNewswire)
Jun-25-26 08:30AM	Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform (GlobeNewswire)
Jun-16-26 08:15AM	Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower (PR Newswire) +27.49%
Jun-15-26 08:30AM	Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing (GlobeNewswire) -13.02%
Jun-08-26 08:30AM	Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program (GlobeNewswire)
Jun-03-26 08:30AM	Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 (GlobeNewswire)
Jun-02-26 09:00AM	The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire) +19.26%
May-27-26 10:36AM	UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine (GlobeNewswire)
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire) +10.18%
May-21-26 12:02PM	Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol 'CNXU' (Newsfile)

Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company was founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell on November 2, 2022 and is headquartered in Reno, NV.

PresidentMr. Miles D. Harrison

FounderMr. David R. Bogart

Ph.D.Dr. Claudia Chavez-Munoz M.D.

CFOMr. Stephen D. Inouye

Chief Medical OfficerDr. Brian K. Pilcher Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Purcell Lynn Sebastian	Director	Jun 18 '26	Buy	0.80	202,500	162,000	2,734,240	Jun 23 08:15 PM
Wright Michael G.	10% Owner	Jun 18 '26	Option Exercise	0.00	250,000	250	2,148,048	Jun 22 01:25 PM
Wright Michael G.	10% Owner	May 26 '26	Option Exercise	0.00	400,000	400	1,898,048	May 28 11:39 AM
Sharpe Jeffrey Nathan	Director	May 22 '26	Option Exercise	0.00	500,000	500	1,000,000	May 26 06:16 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNXU

Conexeu Sciences Inc

Upgrade your Finviz experience